Relmada Therapeutics (RLMD) Tops Q3 EPS by 18c

Relmada Therapeutics (NASDAQ: RLMD) reported Q3 EPS of ($0.73), $0.18 better than the analyst estimate of ($0.91).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• TD Cowen Reiterates Buy Rating on NVIDIA (NVDA), 'unlikely to move significantly on earnings'
• Baidu slips as Q2 results miss estimates despite growth in AI cloud business